Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Drug Resistance, Neoplasm
  • Lung Neoplasms
  • Protein Kinase Inhibitors
  • Receptor, Epidermal Growth Factor

abstract

  • The T790M mutation is common in patients with acquired resistance. The limited spectrum of TKI-resistant mutations in EGFR, which binds to erlotinib in the active conformation, contrasts with a wider range of second-site mutations seen with acquired resistance to imatinib, which binds to ABL and KIT, respectively, in closed conformations. Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anatomic site and mode of binding to the kinase target.

publication date

  • November 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-06-1570

PubMed ID

  • 17085664

Additional Document Info

start page

  • 6494

end page

  • 501

volume

  • 12

number

  • 21